MedPath

Registry and prevalence of gene mutation in Korean patients with familial hypertrophic cardiomyopathy

Not Applicable
Recruiting
Conditions
Diseases of the circulatory system
Registration Number
KCT0000777
Lead Sponsor
Korea Centers for Disease Control and Prevention
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
250
Inclusion Criteria

1. Patients diagnosed as hypertrophic cardiomyopathy
2. Family members of diagnosed patients
3. In cases of juvenile, above age-13(yrs)

Patients (male or female) who is diagnosed as hypertrophic cardiomyopathy following the guidlines, were to be asked and voluntarily participated with signing the consent to participate in research

- Guidelines
a. (Adults) Without the effect of hypertrophy-causing cardiac risks (fabry disease, danon disease, glycogen storage disease, etc.), maximal wall thickness (MWT) are increased more than 15mm in left ventricle with the echocardiography result.
b. (in juveniles(age-13 and above)) MWT are relatively increased as adults with regard to body surface area, and not dilated.

Exclusion Criteria

- Patients and family members who disagreed with the participation of research

Study & Design

Study Type
Observational Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Types of Cardiomyopathy (CMP)
Secondary Outcome Measures
NameTimeMethod
Patient's pedigree infomation
© Copyright 2025. All Rights Reserved by MedPath